A Randomized, Open-Label, Non-Inferiority Study of Intravenous Iron Isomaltoside 1,000 (Monofer) Compared With Oral Iron for Treatment of Anemia in IBD (PROCEED)

OBJECTIVES: In the largest head-to-head comparison between an oral and an intravenous (IV) iron compound in patients with inflammatory bowel disease (IBD) so far, we strived to determine whether IV iron isomaltoside 1,000 is non-inferior to oral iron sulfate in the treatment of iron deficiency anemi...

Descripción completa

Detalles Bibliográficos
Autores principales: Reinisch, Walter, Staun, Michael, Tandon, Rakesh K, Altorjay, Istvan, Thillainayagam, Andrew V, Gratzer, Cornelia, Nijhawan, Sandeep, Thomsen, Lars L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Inflammatory Bowel Disease
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3853365/
https://www.ncbi.nlm.nih.gov/pubmed/24145678
http://dx.doi.org/10.1038/ajg.2013.335

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3853365/
https://www.ncbi.nlm.nih.gov/pubmed/24145678
http://dx.doi.org/10.1038/ajg.2013.335

Ejemplares similares